The Sunbelt Melanoma Trial

Area of Science:

• Oncology
• Surgical Oncology
• Dermatology

Background:

• The Sunbelt Melanoma Trial investigated adjuvant therapies and molecular markers for melanoma.
• Sentinel lymph node (SLN) biopsy is crucial for melanoma staging.
• Completion lymph node dissection (CLND) and high-dose interferon alfa-2b (HDI) are potential treatments.

Purpose of the Study:

• To evaluate the efficacy of HDI therapy in patients with a single positive SLN after CLND.
• To assess the prognostic value of molecular markers (PCR) in SLN-negative patients.
• To determine the role of CLND and adjuvant HDI in PCR-positive patients.

Main Methods:

• A multicenter, prospective randomized clinical study.
• Analysis of disease-free and overall survival in patients receiving HDI.
• Use of polymerase chain reaction (PCR) for molecular staging of SLNs.

Main Results:

• Adjuvant HDI did not improve survival outcomes for patients with a single positive SLN.
• Molecular staging (PCR) did not identify a subgroup of patients at higher risk for recurrence.
• Neither CLND alone nor CLND plus HDI improved survival in PCR-positive patients.

Conclusions:

• High-dose interferon alfa-2b (HDI) is not beneficial for patients with a single positive SLN.
• Molecular staging using PCR did not enhance risk stratification or treatment decisions.
• The trial validated SLN biopsy procedures and provided data for a prognostic risk calculator.